Sofosbuvir Plus Daclatasvir With or Without Ribavirin and Chronic HCV Genotype (GT) 4

Inclusion Criteria: * Non-cirrhotic treatment-naïve participants * FIB-4 \< 3.25 * albumin \> 3.5 * total bilirubin \< 1.2 mg/dl * international normalized ratio (INR) \< 1.2 * platelet count \> 150,000 mm3. * experienced participants who had previously failed treatment with peg-IFN-α-/RBV, SOF/peg-IFN-α +RBV, or SOF/SMV * Naïve cirrhotic participants were confirmed by ultrasonographic features of cirrhosis Exclusion Criteria: * liver disease of non-HCV etiology * hepatitis B or human immune-deficiency virus (HIV) infection * poorly controlled diabetic (HbA1C \> 9) participants * hepatocellular carcinoma * a history of extra-hepatic malignancy within 5 years prior to the study * pregnant or breast feeding * renal disease; serum creatinine \> 2.5 mg/dl or eGFR \< 30 ml/min * evidence of hepatic decompensation; INR \> 1.7, serum albumin \< 2.8 g/dl, total bilirubin \> 3 mg/dl * blood picture abnormalities such as anemia (hemoglobin concentration of 10 g/dl or less) and thrombocytopenia (platelet count \< 50,000 cells/mm3) * major severe illnesses such as congestive heart failure and respiratory failure.